F De Leonardis1, M Govoni, A Lo Monaco, F Trotta. 1. Section of Rheumatology, Department of Clinical and Experimental Medicine, University of Ferrara, 44100, Ferrara, Italy. dlnfnc@unife.it
Abstract
OBJECTIVES: Visceral leishmaniasis (VL) is an extremely rare example of opportunistic infection in patients treated with TNF-alpha antagonists and only a few cases have been described. In this paper risk factors, clinical features, diagnostic work-up and outcome of patients developing VL under biologic therapy are described. METHODS: Case report and review of the published cases of VL in patients under biologic treatment. RESULTS: We retrieved six patients, including ours, all of whom presented anarchic fever and pancytopenia. In 5 cases, splenomegaly was detected. The same number of patients came from endemic areas for VL. In the majority of the cases a bone marrow examination was not diagnostic, requiring the performance of a second one and/or the execution of other diagnostic tests. One fatal outcome was observed. CONCLUSION: Even if VL represents a sporadic complication of biologic treatments, its presence should always be suspected in patients developing a triad of signs and symptoms constituted by fluctuant fever, pancytopenia and splenomegaly, especially if coming from endemic areas. In these cases an extensive diagnostic work-up must be warranted. Atypical and confusing features may resemble autoimmune diseases at presentation and during the course of the illness.
OBJECTIVES:Visceral leishmaniasis (VL) is an extremely rare example of opportunistic infection in patients treated with TNF-alpha antagonists and only a few cases have been described. In this paper risk factors, clinical features, diagnostic work-up and outcome of patients developing VL under biologic therapy are described. METHODS: Case report and review of the published cases of VL in patients under biologic treatment. RESULTS: We retrieved six patients, including ours, all of whom presented anarchic fever and pancytopenia. In 5 cases, splenomegaly was detected. The same number of patients came from endemic areas for VL. In the majority of the cases a bone marrow examination was not diagnostic, requiring the performance of a second one and/or the execution of other diagnostic tests. One fatal outcome was observed. CONCLUSION: Even if VL represents a sporadic complication of biologic treatments, its presence should always be suspected in patients developing a triad of signs and symptoms constituted by fluctuant fever, pancytopenia and splenomegaly, especially if coming from endemic areas. In these cases an extensive diagnostic work-up must be warranted. Atypical and confusing features may resemble autoimmune diseases at presentation and during the course of the illness.
Authors: José M Ramos; Rafael León; Esperanza Merino; Marta Montero; Asunción Aljibe; Marino Blanes; Sergio Reus; Vicente Boix; Miguel Salavert; Joaquín Portilla Journal: Am J Trop Med Hyg Date: 2017-10-10 Impact factor: 2.345
Authors: Amanda S Cavalcanti; Marcelo Ribeiro-Alves; Luiza de O R Pereira; Gustavo Leandro Mestre; Anna Beatriz Robottom Ferreira; Fernanda N Morgado; Mariana C Boité; Elisa Cupolillo; Milton O Moraes; Renato Porrozzi Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240
Authors: Pau Bosch-Nicolau; Maria Ubals; Fernando Salvador; Adrián Sánchez-Montalvá; Gloria Aparicio; Alba Erra; Pablo Martinez de Salazar; Elena Sulleiro; Israel Molina Journal: PLoS Negl Trop Dis Date: 2019-08-30
Authors: Katharina Arens; Christodoulos Filippis; Helen Kleinfelder; Arthur Goetzee; Gabriele Reichmann; Peter Crauwels; Zoe Waibler; Katrin Bagola; Ger van Zandbergen Journal: Front Immunol Date: 2018-07-31 Impact factor: 7.561